Registered User Login
Asian Journal of Research in Pharmaceutical Sciences
ISSN: 2231-5659(Online), 2231-5640(Print)
News & Conferences
Volume No. :
Issue No. :
ISSN Print :
ISSN Online :
Click to Login
Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate
Sandip S. Kshirsager
Dr. Siraj N. Shaikh
Narendra B. Patil
Ketan B. Patil
Sandip S. Kshirsager1*, Dr. Siraj N. Shaikh1, Narendra B. Patil2, Ketan B. Patil2
1Department of Pharmaceutics, Ali Allana College of Pharmacy, Akkalkuwa, Maharashtra
2Department of Pharmacology, Ahinsa Institute of Pharmacy, Dondaicha, Dist-Dhule, Maharashtra
Cancer is leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018.Breast cancer 2.09 million death in 2018. Approximately 70% of deaths from cancer occurs in low- and middle-income countries. Human epidermal growth factor receptor (HER) 2 is overexpressed in 20 -25% of breast cancer and has historically been poor prognostics marker. Niratinib maleate is an anti breast cancer drug .it is crystalline form and chemically (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl) methoxy] phenyl] amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino) but-2-enamide maleate. It an oral, irreversible pan-Erb B receptor tyrosine kinase inhibitor and it can effectively inhibit the activity of Erb B1, ErbB2 tyrosine kinase.
Breast cancer, tyrosine kinase, Niratinib maleate, HER (Human epidermal growth factor receptor).
Sandip S. Kshirsager, Dr. Siraj N. Shaikh, Narendra B. Patil, Ketan B. Patil. Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate. Asian J. Res. Pharm. Sci. 2020; 10(2):100-102.
Visitor's No. :